Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia K Tietze

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Dermatologie (Heidelberg, Germany)|November 18, 2022
[Tumor-infiltrating natural killer and T cells in melanoma]Julia K Tietze
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 26, 2024
Higher intraoperative detection rate of suspicious non-palpable lesions using wire marking in skin cancer patientsJulia K Tietze, Steffen Emmert, Paulina Troitzsch, et al.
European Journal of Immunology|November 24, 2007
Characterization of mouse CD4 T cell subsets defined by expression of KLRG1Niklas Beyersdorf, Xin Ding, Julia K Tietze, et al.
Cancer Immunology, Immunotherapy : CII|May 13, 2017
Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumabMarkus V Heppt, Ilana Goldscheider, Julia K Tietze, et al.
Current Opinion in Oncology|January 21, 2015
Combination therapy of melanoma using kinase inhibitorsMarkus V Heppt, Julia K Tietze, Saskia A Graf, et al.
Experimental Dermatology|November 29, 2016
Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapyJulia K Tietze, Daniela Angelova, Markus V Heppt, et al.
International Reviews of Immunology|November 8, 2011
Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Julia K Tietze, Gail D Sckisel, Hui-Hua Hsiao, et al.
Frontiers in Immunology|October 17, 2025
Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapyDionysios Garmpis, Guillermo Hidalgo-Gadea, Cornelia Mauch, et al.
Oncology|August 14, 2023
Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with IpilimumabDaniela Angelova-Toshkina, Benjamin Weide, Lutz F Tietze, et al.
European Journal of Dermatology : EJD|May 8, 2023
Evaluation of the heat sensitivity of Trichophyton rubrum and Trichophyton interdigitaleKatharina Seidel, Lutz F Tietze, Christian Braun, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Dermatologie (Heidelberg, Germany)|November 18, 2022
[Tumor-infiltrating natural killer and T cells in melanoma]Julia K Tietze
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 26, 2024
Higher intraoperative detection rate of suspicious non-palpable lesions using wire marking in skin cancer patientsJulia K Tietze, Steffen Emmert, Paulina Troitzsch, et al.
European Journal of Immunology|November 24, 2007
Characterization of mouse CD4 T cell subsets defined by expression of KLRG1Niklas Beyersdorf, Xin Ding, Julia K Tietze, et al.
Cancer Immunology, Immunotherapy : CII|May 13, 2017
Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumabMarkus V Heppt, Ilana Goldscheider, Julia K Tietze, et al.
Current Opinion in Oncology|January 21, 2015
Combination therapy of melanoma using kinase inhibitorsMarkus V Heppt, Julia K Tietze, Saskia A Graf, et al.
Experimental Dermatology|November 29, 2016
Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapyJulia K Tietze, Daniela Angelova, Markus V Heppt, et al.
International Reviews of Immunology|November 8, 2011
Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Julia K Tietze, Gail D Sckisel, Hui-Hua Hsiao, et al.
Frontiers in Immunology|October 17, 2025
Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapyDionysios Garmpis, Guillermo Hidalgo-Gadea, Cornelia Mauch, et al.
Oncology|August 14, 2023
Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with IpilimumabDaniela Angelova-Toshkina, Benjamin Weide, Lutz F Tietze, et al.
European Journal of Dermatology : EJD|May 8, 2023
Evaluation of the heat sensitivity of Trichophyton rubrum and Trichophyton interdigitaleKatharina Seidel, Lutz F Tietze, Christian Braun, et al.
Pageof 4